Form 4: Amneal Pharmaceuticals Director Shlomo Yanai Reports Stock Unit Vesting

Director Shlomo Yanai of Amneal Pharmaceuticals reports the vesting of 76,453 restricted stock units, convertible to Class A Common Stock, on May 10, 2024.

Summary

• On May 10, 2024, Shlomo Yanai, a director of Amneal Pharmaceuticals, reported the vesting of 76,453 restricted stock units.
• These restricted stock units convert into shares of the company's Class A Common Stock.
• Following the transaction, Yanai directly owns 245,727 shares of Class A Common Stock.
• The restricted stock units were initially granted on May 9, 2023, and vested on May 10, 2024.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing indicating the vesting of stock units, which is a neutral event. It reflects standard compensation practices.

Positives

• The vesting of restricted stock units aligns the director's interests with those of the shareholders.
• The director now directly owns 245,727 shares of Class A Common Stock.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.

Stakeholder Impact

• The vesting of stock units aligns the director's interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates